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Roles in Breast Tumorigenesis
Abrar Jamous and Zaidoun Salah*
Al Quds-Bard College for Arts and Sciences, Al Quds University, Abu Dis, Palestine
Protein-protein interactions are key factors in executing protein function. These
interactions are mediated through different protein domains or modules. An important
domain found in many different types of proteins is WW domain. WW domain-containing
proteins were shown to be involved in many human diseases including cancer. Some
of these proteins function as either tumor suppressor genes or oncogenes, while others
show dual identity. Some of these proteins act on their own and alter the function(s)
of specific or multiple proteins implicated in cancer, others interact with their partners
to compose WW domain modular pathway. In this review, we discuss the role of
WW domain-containing proteins in breast tumorigenesis. We give examples of specific
WW domain containing proteins that play roles in breast tumorigenesis and explain
the mechanisms through which these proteins lead to breast cancer initiation and
progression. We discuss also the possibility of using these proteins as biomarkers or
therapeutic targets.
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INTRODUCTION
Protein function is determined by the domains and motifs that it harbors. These domains can be
functional domains such as the catalytic domains found in many enzymes, or structural domains
that are important for protein-protein interactions or the assembly of multi-protein complexes.
Thus, protein’s function is determined by its catalytic activity and its partners. One of these
important domains found in many proteins is the WW domain. WW domain, is the smallest
naturally occurring module. It consists of ∼35–40 amino acids, including two highly conserved
tryptophans (W), after which the module is named (WW). The two Ws are separated by 20–23
amino acids (1). Based on their ligand preference, WW domains are classified into five different
classes. WW domains are very important domains that are involved in very critical cellular
processes including; transcription, splicing, ubiquitination, apoptosis, cell growth, proliferation,
and differentiation (2). Because of its link to many critical cellular processes and its widespread
distribution among many proteins, WW module is linked to many diseases including; Liddle’s
syndrome of hypertension, muscular dystrophy, Alzheimer’s and Huntington’s diseases, and cancer
(1, 2).
WWOX AND BREAST TUMORIGENESIS
WW domain oxidoreductase (WWOX) is a tumor suppressor gene, which is altered in different
types of cancer, including breast cancer (3). In breast cancer, WWOX gene is lost even in
pre-invasive stages (4, 5). Moreover, recent studies have shown a correlation between WWOX
expression and the clinical outcome of breast cancer (6–10).
Jamous and Salah WW Domains and Breast Cancer
In addition to clinical data that supports WWOX role
in breast tumorigenesis, different animal models have proved
its function in proper mammary gland development and
tumorigenesis. It was shown that WWOX is highly expressed
in mammary gland tissue and that its targeted deletion results
in mammary gland fibroadenoma (11), as well as impaired
mammary gland development (12, 13). Moreover, it was shown
that aging WWOX-heterozygous C3H knockout mice develop
higher incidence of mammary tumors. These tumors bear altered
gene expression that resembles altered gene expression in human
breast cancer (14).
WWOX mediates its functions by interacting with and
modulating the activities of different proteins either through
its WW domains or in a WW domain independent manner.
Nonetheless, WWOX has also an oxidoreductase domain that
seems to play a role in tumorigenesis too. WWOX alters different
cellular processes involved in tumorigenesis. As discussed
below, these cell activities include apoptosis, genomic instability,
metabolism and metastasis.
WWOX Function in Breast Cancer Cell
Apoptosis
Different published findings have linked WWOX to apoptosis.
It was revealed that WWOX overexpression or endogenous
WWOX reactivation in breast cancer cells leads to apoptotic
cell death in vitro and suppression of breast tumor growth in
vivo. These effects are mediated by reducing the expression
levels of the anti-apoptotic protein Bcl-2 and inducing the
pro-apoptotic protein BCL2-associated X protein (Bax) (15)
(Figure 1). Furthermore, WWOX was shown to interact with
p73β in MCF7 breast cancer cell line (Figure 1). This interaction,
although was not tested in breast cancer cells, leads to a
cytoplasmic p73β dependent cell death (16). WWOX was also
shown to interact and stabilize p53 and confer cellular sensitivity
to apoptotic stress (17). Another study demonstrated that
WWOX induces breast cancer cell apoptosis by triggering Smad4
transcriptional activity (Figure 1) (18). In the clinical context of
cell death and apoptosis, WWOX was shown to interact with two
very important factors involved in hormone treatment resistance.
These factors include activating protein 2γ (AP2γ) and WW
domain-binding protein 2(WBP2) (Figure 1). WWOX interacts
with AP2γ and sequesters it in the cytoplasm and inhibits its
transactivational function (19). For WBP2, WWOX physically
interacts withWBP2 and suppresses ER transactivation pathways
(Figure 1) (20).
WWOX and Genomic Instability in Breast
Cancer
Genomic instability is one of the important cancer hallmarks
involved in tumor initiation as well as tumor progression (21, 22).
WWOX was recently assigned an important function in DNA
damage response (DDR) (23). Abu-Odeh et al. demonstrated
that WWOX interacts with Ataxia telangiectasia mutated (ATM)
and activates both ATM and Ataxia telangiectasia mutated
RAD3-related (ATR) following DNA damage. They also showed
that WWOX knockdown is associated with less activation of
DDR signaling molecules, and consequently less efficient DNA
repair and thus more genomic instability (Figure 2) (23, 24).
In the context of response and resistance of cells to DNA
damaging therapies, a recent study found thatWWOX deficiency
increases survival of cells after ionizing radiation-induced
double strand breaks (DSBs), and that WWOX restoration
in MDA MB231 breast cancer cells, that lack endogenous
WWOX, leads to reduced survival upon gamma irradiation.
On the contrary, WWOX-silenced cells survived bleomycin
treatments as compared to WWOX-expressing MCF10A cells
(25). Moreover, in this study, WWOX interaction with Breast
Cancer gene1 (BRCA1) was shown to affect DNA DSB repair
pathway choice and thus affects cell response to DSB inducing
agents (25, 26). These findings prove that WWOX plays an
important role in DDR and genomic stability, which might make
it a marker for the success of DDR-targeting biological therapies.
Since WWOX seems to play a very important role in DDR, and
that its loss impairs the repair process and leads to genomic
instability, it will be interesting to see whetherWWOX loss would
enhance the activity of PARP inhibitors. Here, based on PARP
inhibitors mechanism of action, it is expected that cells that lack
WWOX will be more sensitive to this type of therapy.
WWOX and Cancer Metabolism
Another cancer hallmark connected to the tumor suppressor
gene WWOX is cell metabolism. The connection between
WWOX and cancer cell metabolism was established after
linking WWOX protein to Hypoxia-inducible factor 1-alpha
(HIF1α) function (27). In this study, it was found that WWOX
interacts with HIF1α and modulates its transcriptional activity
(Figure 3). In breast cancer cells, the authors showed that
WWOXknock down increases HIF1α inMCF7 cells (27). Finally,
they demonstrated that WWOX expression inversely correlates
with HIF1α target gene Glucose transporter 1 gene (Glut1) in
breast cancer tissue samples (27) (Figure 3). These findings and
others all point to the fact that WWOX is very important in
modulating cancer cell metabolism in general and breast cancer
cells specifically. Since WWOX function is usually lost in breast
cancer, it will be interesting to test whether a small molecule
that resembles WWOX WW domain would inhibit the function
of HIF1α and shifts cancer cell metabolism from a glycolysis
dependent to a normal metabolism.
Metastasis
Most of cancer patients die from metastasis and not from
primary tumors. WWOX was also found to play a role
in breast cancer metastasis. Loss of WWOX expression in
breast cancer is significantly associated with the number of
metastatic axillary lymph nodes and poor survival (28). In
addition, WWOX was shown to play an important role in
hepatocyte growth factor (HGF) mediated mesenchymal to
epithelial transition (MET) in breast cancer bone metastasis (29).
Another study demonstrated that the chemotherapeutic drug 5-
aza-2′-deoxycytidine (decitabine), increases WWOX expression
and localization to the nucleus in bone metastasis xenograft
model. It was proposed that the elevation in WWOX expression
is responsible for altering the HGF/Met/E.cadherin signaling
Frontiers in Oncology | www.frontiersin.org 2 December 2018 | Volume 8 | Article 580
Jamous and Salah WW Domains and Breast Cancer
FIGURE 1 | Effect of some WW domain proteins on cell death. WWOX induces cell death by (A) inducing BAX levels and decreasing BCL2 levels. (B) Upon
hylauronan treatment WWOX complexes with hyaluronidase and Smad4. This complex translocates to the nucleus and induces the expression of Smad4
pro-apoptotic target genes. (C) WWOX binds to P73b and induces its cytoplasmic dependent cell death. (D) WWOX binds and sequesters WBP2 and AP2γ in the
cytoplasm. This inhibits their treatment resistance phenotype. E3 ligases also manipulate breast cancer cell death. WWP1 inhibits TRAIL mediated cell death. ITCH by
inhibiting RASSF5 prevents apoptosis and activates cell cycle.
FIGURE 2 | WW domain protein roles in genomic stability. Upon DNA damage, ATR and ATM get activated. When activated, they can phosphorylate and activate the
E3 ligase ITCH. Active ITCH can further ubiquitinate and activate WWOX leading to its translocation to the nucleus. In the nucleus, WWOX, in a positive feedback loop
activates ATM and ATR and enhances DNA damage response and repair. Moreover, WWOX can interact with BRCA1 and enhance Non-homologous end joining over
homologus recombination repair pathway. E3s also play roles in genomic stability too. SMURF2 increase genomic stability by inhibiting the activity of RNF20/hBre1A,
the major ubH2B-specific E3 and by stabilizing topoisomerase IIa (Topo IIa). ITCH enhances genomic integrity by increasing the efficiency of DNA damage repair
(DDR). Upon DNA damage ITCH is activated by ATM. Active ITCH can further ubiquitinate and activate WWOX leading to its translocation to the nucleus. In the
nucleus, WWOX, in a positive feedback loop, activates ATM and ATR and enhances DNA damage response and repair.
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FIGURE 3 | WWOX modulates cancer cell metabolism. When WWOX is present it binds to HIF1α and inhibits its transcriptional activity. Moreover, WWOX increases
HIF1α hydroxylation and increase its degradation. As a consequence WWOX reduces glucose uptake, decreases glycolysis and increase mitochondrial respiration.
axis and thus reducing breast cancer metastasis to the bone
(30). In a different study that examined the role of WWOX
and Transcriptional coactivator with PDZ-binding motif (TAZ)
in breast metastasis to bone, WWOX and TAZ increased
invasiveness of the bone metastasis-derived clone 1,833 (these
cells were derived from MDA MB-231 metastasis to the bone)
(31). This effect on 1,833 clone was explained by the fact that
overexpression of WWOX and TAZ increases E.cadherin levels,
which is an event believed to be important inMET and successful
bone metastasis. Interestingly, in the same study, WWOX
overexpression didn’t alter E.cadherin levels and inhibited the
invasion capability of the 1,833 clone parental cells, MDA MB-
231 (31). These findings and others indicate that at least some
of WWOX suppressive functions are cell context specific, and
that experiments questioning WWOX functions should be better
designed and defined.
Questioning WWOX Suppressive Functions
Although the compelling evidence that indicates with no doubt
that WWOX is a tumor suppressor gene, the presence ofWWOX
in a fragile locus in the genome raises suspicion about its identity
of being a classical tumor suppressor gene. As well, its localization
in a fragile sequence raises another question on why such an
important gene lies in a damage prone locus? The answer to this
question might be that loss of WWOX can act as an early alarm
for the cell to respond to different types of insults that can lead to
cell stress and DNA damage.
Moreover, WWOX tumor suppressive function was
questioned in different research articles. For example, in a
publication by Watanabe et al., it was found that WWOX is
expressed in 48 cell lines out of 49. Moreover, it was shown that,
using immunohistochemistry staining, WWOX is not down
regulated in cancer tissue (32). However, a careful inspection
of the data presented by Watanabe et al. showed the following:
first, there was no normal control cells to which the expression
of WWOX was compared and second, the expression of WWOX
in the tested cell lines varied and there were at least 16 cell lines
that showed a very low WWOX expression when compared to,
for example, MCF7 cell line. These results indicate that WWOX
loss in cancer is not a black and white phenomenon, but like
many other tumor suppressor genes, WWOX expression is very
heterogeneous in cancer samples. In addition, the expression
of a tumor suppressor gene in a cancer sample or cell line does
not preclude it from being a tumor suppressor gene, since a
tumor suppressor gene might be expressed in a cell line but is not
functional. This might be due to a posttranslational modification,
mislocalization or the lack of its partner in a specific tumor type.
Another paper showed that WWOX might have a role in cancer
progression toward a pre metastatic state in vivo (33). In this
article, Chang et al. showed that WWOX1 and 2 expression
upregulation and Tyr33 phosphorylation correlates with the
progression of breast cancer to a pre-metastatic state. Although
the authors showed evidence that WWOX is overexpressed in
pre-metastatic cancer, the conclusion that WWOX may play
function in tumor progression might not be accurate for the
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following reasons. First, the authors tested the expression of
WWOX on different tumor grades obtained from different
patients and not on different stages from the same patient, which
means that the authors didn’t compare the staining pattern to
the baseline of the same patient. Second, the fact that WWOX
expression is induced in pre-metastatic stage of breast cancer
does not exclude the possibility that WWOX expression is
induced in order to suppress tumor progression rather than
promoting it, analogous to p53 stabilization after stress. These
controversial findings indicate that the molecular mechanisms
that regulate WWOX function as well as the molecular functions
mediated by WWOX should be investigated in more depth
since at least WWOX partners can have dual and controversial
functions. For example, ITCH, a WWOX partner and a WW-
domain protein, was found to play an important role in DDR
and genomic stability (anti-tumorigenic effect) (23, 24). On
the other hand ITCH in the context of the Hippo pathway was
shown to have a pro-tumorigenic function (34, 35). This raises
the question; How does WWOX affect ITCH pro-tumorigenic
function? Does it antagonize ITCH function and suppresses
tumor growth? Which is the expected scenario, or does it work
synergistically with ITCH like under DDR and thus promotes
tumorigenesis?
A very interesting aspect of WWOX tumor suppressive
function is changing the signaling pathway of different
proteins to achieve the same outcome. For example, p73 is
a tumor suppressor gene that induces apoptosis through its
transcriptional transactivation function. WhenWWOX interacts
with p73, paradoxically after WWOX activation with the Src
oncogene, it sequesters p73 in the cytoplasm and inhibits its
transactivation function. Although this has a negative effect on
p73 nuclear function, it enhances p73-WWOX interaction in
the cytoplasm leading to apoptosis. This raises the following
questions; why does WWOX interfere with p73 nuclear
pro-apoptotic function to induce apoptosis via a different
mechanism? Is cell context the only reason for this? Or is it
because WWOX’s pro-apoptotic function is superior to p73 pro-
apoptotic function?
Although the controversy about WWOX function, it will
be exciting to try to test how would peptides that resemble
WWOX WW domains affect cancer cell behavior to evaluate
their therapeutic functions.
HIPPO PATHWAY AND BREAST CANCER
The Hippo pathway is a highly conserved pathway that regulates
many cellular functions including cell proliferation, growth,
differentiation and apoptosis (2). The pathway is composed
of mainly a core cascade of kinases that include Macrophage-
stimulating protein 1/2 (MST1/2) and Large tumor suppressor
kinase 1/2 (LATS1/2). These kinases, when activated lead to
the phosphorylation, sequestration and inactivation of two WW
domain downstream effector proteins; yes-associated protein
(YAP) and TAZ (Figure 4). The pathway is enriched with
WW domain mediated interactions on the level of upstream
modulators, core components, as well as downstream effectors
(Figure 4) (1, 36, 37).The pathway is either inactivated or harbors
a mutation in one of its components in many types of cancer;
including breast cancer.
Animal Models and Clinical Data as
Evidence for YAP/TAZ Roles in Breast
Cancer
In different animal models, YAP and TAZ functions supported
tumor initiation and progression (38, 39). In the clinical context,
TAZ was shown to have a negative prognostic effect that
correlates with shorter disease-free survival (DFS) of breast
cancer patients (40) and negatively correlates with treatment
outcome (41). In luminal A breast cancer samples, YAP1
expression levels negatively correlates with Estrogen positive
(ER+) samples, and positively correlates with proliferation in
ER- samples. Moreover, in the same study, low YAP1 levels
correlated with impaired response to tamoxifen treatment (42).
In a different study YAP nuclear levels were higher in metaplastic
breast cancer tumors when compared to triple negative tumors
(43). In another study that examined the expression of YAP
in different molecular types of breast cancer, cytoplasmic and
phospho-YAP levels were elevated in HER-2 breast cancer
type. In this molecular subtype, cytoplasmic YAP expression
concurred with poorer disease free survival. In addition, nuclear
YAP staining was associated with shorter overall survival (44).
In contrast to all findings that revealed that YAP expression
correlates with a more aggressive breast cancer and with a poor
survival and disease free rates, a recent study by Cao et al.
demonstrated that YAP expression is associated with the low
grade type of breast cancer luminal A. In addition, the study
revealed that YAP expression correlates with favorable DFS and
overall survival in patients with luminal A breast cancer and
with favorable DFS association among patients with invasive
ductal carcinoma, luminal B (HER2-), and luminal B (HER2+)
breast cancers (45). These results indicate that there is still
some controversy about YAP expression and its correlation with
clinical outcome in breast cancer clinical samples. Of course
these controversies can be related to different reasons starting
from very technical issues related the staining techniques, the
antibodies used in each study to data scoring and data analysis.
While these can still be possibilities, other biological reasons can
still be an explanation. For example, other genetic factors and
expression profiles of many other different proteins, in addition
to YAP status, that were not tested in most of the studies can
provide explanations.
YAP/TAZ Roles in Breast Cancer Cell
Transformation and Tumorigenesis
In addition clinical data, it is obvious that YAP and TAZ play
critical roles in breast tumorigenesis. For example, YAP over
expression in MCF10A, non-transformed mammary gland cells,
increases cell proliferation, anchorage independent growth and
inhibits apoptosis (38). On the other hand, YAP knockdown
results in cell growth inhibition in vitro and ex vivo tumor
formation (46). In different studies, YAP oncogenic function
was related to Hippo pathway malfunction. For example, it
was demonstrated that LATS1degradation mediated by ITCH
releases YAP function and enhances breast cell tumorigenicity
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FIGURE 4 | Inactivation of the Hippo pathway induces breast cancer metastasis. The factors labeled in red are examples of proteins that inactivates the Hippo
pathway and induces metastasis. PAR1 activation and the kinase MARK4 destabilize the core complex and inhibits its activity. MARK4 can increase nuclear YAP and
TAZ too. The activation of HER3 by ROB1 leads to the assembly of a complex between MAYA ncLRNA, LLGL2 and the methyl transferase NSUN6 that methylates
and inactivates MST1. Abl kinases can also increase nuclear TAZ. Finally, TAZ and HIF1 and reciprocally act as transcription co activators for each other. The only
Hippo pathway activator shown here is SKI which binds LATS2 and MST1 and strengthen the core complex.
in vivo and in vitro (34, 35). Similar to YAP, TAZ was shown
to be involved in breast tumorigenesis. While overexpression
of TAZ in MCF10A cells causes transformation morphologic
changes, TAZ knockdown reduces their tumorigenicity in vitro
and in vivo (47). Similar to YAP, uncoupling of TAZ from the
inhibitory effect of the Hippo pathway, upon LATS1 knock
down, enhances TAZ-mediated phenotypes (48). Moreover,
TAZ transforming activity was shown to be dependent on
Transcriptional enhancer factor TEF-1 (TEAD) transcriptional
activity (49). On the mechanism level, it was demonstrated that
coordination between YAP, TAZ and Transforming growth factor
beta (TGFβ executes a specific pro-tumorigenic transcriptional
program that is important for overcoming the anti-tumorigenic
effect of TGFβ. In addition, TAZ was shown to stabilize Krüppel-
like factor 5 (KLF5) which promotes breast cell proliferation
and tumorigenesis by competing with the E3 ubiquitin ligase
WW-domain protein1(WWP1) on KLF5 (48).
YAP/TAZ Roles in Breast Cancer
Metastasis
The link between the Hippo pathway and YAP/TAZ mediated
breast cancer metastasis was proved in different publications.
For example, Ski interacts with LATS2, Sav, Mob, and Mer and
facilitates the phosphorylation of YAP and TAZ, which leads to
inhibition of YAP/TAZ induced transformation and epithelial to
mesenchymal transition (EMT) (Figure 4) (50). In another study,
activation of human epidermal growth factor receptor 3 (HER3)
by ROR1 was shown to recruits the adaptor protein LLGL2,
lncRNAMAYA (MST1/2-Antagonizing for YAP Activation), and
methyltransferase NSUN6 (Figure 4). This leads to methylation
and inactivation of MST1, which liberates YAP and increases
breast cancer cell metastasis to the bone (51). Recently, it
was demonstrated that TWIST, via the activation of thrombin
receptor PAR1, inactivates the Hippo pathway and induces EMT
and promotes breast cancer cell invasion (Figure 4) (52). Also,
it was shown that TAZ and HIF1α interaction progresses breast
cancer metastasis (Figure 4) (53, 54). Different kinases were
also shown to promote breast cancer cell migration through
inactivating the Hippo pathway. These kinases include ABL and
MARK4 kinases (55, 56). In addition to these studies, different
other studies have shown that YAP and TAZ lead to breast cancer
migration, invasion and metastasis (38, 40, 47, 57, 58).
Hippo Pathway and BC Stem Cells
The link between BCSC and the Hippo pathway was initially
established in a study that demonstrated that TAZ is required
to sustain self-renewal and tumor-initiation capacities in BCSCs
(59). TAZ was also shown to be overexpressed in tumors derived
from BCSC compared to tumors derived from non-BCSC (40).
In addition, overexpression of TAZ in non-transformed basal
cells (MCF10A) confers cancer stem cell phenotype in these
cells (60). Moreover, TAZ is indirectly tied to breast cancer
stemness after the finding that revealed that miRNA125, by
targeting the Hippo pathway and activator leukemia inhibitory
factor receptor (LIFR), induces TAZ activity and breast cancer
stemness (Figure 5) (61). On the mechanism level, TAZ was
found to be involved in a positive feedback loop that activates
the expression of α5 subunit of laminin (LM) 511 and the
formation of a LM511 matrix. Reciprocally, LM511 activates
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FIGURE 5 | Hippo pathway activity and breast cancer cell stemness. Different mechanisms responsible for Hippo pathway inactivation are illustrated in this figure.
miRNA125 targets the Hippo pathway activator LIFR and induces TAZ activity. Also, TAZ was found to activate the expression of α5 subunit of laminin (LM) 511 and the
formation of a LM511 matrix. Reciprocally, LM511 activates α6Bβ1 integrin that activated TAZ. Finally, TWIST increases PAR1 expression which consequently inhibits
the Hippo pathway and induces TAZ function. TAZ activation through all these mechanisms increases the expression of breast cancer cell stemness related genes.
α6Bβ1 integrin, which activates TAZ and promotes breast cancer
stemness (Figure 5) (62). Moreover, TWIST increases PAR1,
which was shown to inhibit the Hippo pathway and induce
breast cancer stemness phenotype by activating TAZ (Figure 5)
(52). YAP was also connected to breast cancer cell stemness.
YAP overexpression upregulates mammary stem cell (MaSC)
signature genes (63) (Figure 5). Moreover, it was concluded that
YAP is more important in cancer stemness in basal-like breast
cancer compared with luminal-type breast cancer and that YAP
correlates with poor relapse-free survival specifically in basal-like
breast cancer compared to luminal-type breast cancer (63).
Recently, in breast cancer patient samples, high YAP
expression profiles correlated with EMT and stemness gene
signature enrichment (64). Finally, in an attempt to study the
role of Hippo pathway in mammary gland development and
tumor formation using gland reconstitution, it was found that
Hippo signaling is involved in mammary tumor formation but
not essential for mammary gland development (65).
Immune Evasion
Immune evasion, or escape from immune system control is one
of Cancer “Hallmarks” (21). Paradoxically, it is documented that
the presence of intact and functional immune system can prevent
or promote carcinogenesis by a process known as “Cancer
Immuno editing” (66–68). Accordingly, immunotherapy gained
interest and is seen promising in curing cancer. Recently,
it has been published that either deletion of LATS1/2 or
overexpression of YAP/TAZ increases tumor immunogenecity
and thus enhance its destruction by the immune system in
vivo (69). These findings, to some extent, contradict previous
work that showed that LATS1/2 are tumor suppressor genes and
YAP/TAZ are oncogenes. In contrast to these findings about
the immune activating function of YAP, it was shown that YAP
overexpression induces an immunosuppressive environment
(70, 71). In breast cancer, a recent work revealed that while
LATS1/2 and MST1/2 reduce the expression of the immune
checkpoint molecule PD-L1 in cancer cells, YAP/TAZ have an
opposite effect (72). Since PD-L1 has an immunosuppressive
function, these results are in concordance with the previous
results that YAP/TAZ are immunosuppressive (70, 71) rather
than being more immunogenic (69). Since PD/PD-L1 interaction
is currently targeted for cancer immunotherapy, these findings
suggest that YAP/TAZ might be used as a predictive factors for
PD/PD-L1 based cancer immunotherapy.
Therapeutic Potential of the Hippo
Pathway
Based on various roles played by the Hippo pathway and its
downstream effectors YAP and TAZ in breast cancer, it seems
that modulating the activity of the Hippo pathway holds a hope
of being therapeutic target in breast cancer. In fact there are
different compounds that were used and showed an effect on
YAP/TAZ functions. For example, Verteporfin treatment inhibits
proliferation, invasion andmigration of the breast cancer cell line
MDA MB231 (73). This effect of Verteporfin was observed with
other types of cancer (74–77). Other molecules that have anti-
tumorigenic effect by attenuating YAP/TAZ function are statins,
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which inhibit the synthesis of geranylgeranyl pyrophosphate
produced by the mevalonate cascade. This product stimulates
Rho GTPases and in turn activates YAP/TAZ by inhibiting their
phosphorylation. Thus, by inhibiting mevalonate cascade, statins
inhibit YAP/TAZ activity (78). In breast cancer, simvastatin
was shown to down regulate the expression of the downstream
gene RHAMM. This attenuates breast cancer cell invasion and
motility induced by signal–regulated kinase (ERK). Of note,
these outcomes were revealed to be independent of MST and
LATS kinase activities (79). In another study, combinations of
Dasatinib and statins (which induce YAP/TAZ phosphorylation)
and pazopanib (which induces proteasomal degradation of
YAP/TAZ), with other anti-cancer drugs, like doxorubicin
and paclitaxel, inhibited YAP/TAZ-dependent breast cancer
cell proliferation. For example, in MDA MB231 cell line,
which is YAP/TAZ dependent, these combinations synergistically
reduced cell viability and tumorigenicity in vitro. On the other
hand, in MCF7 cells, which are YAP/TAZ independent, these
combinations didn’t show the effects observed in MDA MB231
(80). The fact that different cells respond differently to YAP/TAZ
inhibition indicates that other biomarkers play a role in cell
response to therapy and not only the presence or absence of a
single molecule like YAP and TAZ. Thus, future studies should
address the effect of targeting YAP/TAZ, and concentrate on
wider analysis and profiles of other proteins related to the
functions of YAP/TAZ. Also, as discussed below, there is no
consensus about YAP functions in breast carcinogenesis. In
addition, it is always mandatory to perform drug screening
experiments in a model that recapitulates what happens in
tumors in vivo. In relation to this, while different studies
revealed that Hippo pathway activation or YAP/TAZ inactivation
results in an anti-tumorigenic outcome, It was found that
inactivation of the Hippo pathway (by LATS1/2 knockdown or
YAP/TAZ overexpression) increases tumor immunogenecity and
thus enhances its destruction by the immune system in vivo (69).
Over all, although the results from Hippo pathway manipulation
in cell lines and animal models makes it a potential therapeutic
target in cancer, it seems that a lot is still needed to be done to
prove the reproducibility of these results in breast cancer patients.
Controversies About YAP Oncogenic
Functions
As discussed above, compelling evidence proved that TAZ
has only pro-tumorigenic functions. On the other hand,
research regarding YAP function in cancer still holds some
controversies. For example, YAP interacts with p73 and increases
its transcriptional activity (81). This YAP-p73 interaction is
important in driving p73 gene-target specificity in response
to DNA damage (82). Moreover, under DNA damage YAP1
protects p73 from ITCH mediated degradation and thus induces
p73-dependent apoptotic response (83). In breast cancer too,
YAP has tumor suppressive functions. For example, it was
demonstrated that YAP locus undergoes loss of heterozygosity,
which might indicate that the YAP locus (11q22–23) harbors
a tumor suppressor (84, 85). In addition, it was demonstrated
that YAP has a pro-apoptotic function that can be inhibited
by AKT oncogene (86). Moreover, knockdown of YAP in
breast cancer cell lines suppressed anoikis, increased migration
and invasiveness, inhibited response to taxol and enhanced
tumor growth in nude mice (87). Finally, it was revealed that
MicroRNA-200a promotes anoikis resistance and metastasis by
targeting YAP1 in human breast cancer (88).
This controversy about YAP tumor suppressor and oncogenic
functions can be explained, at least in part, by the fact that
YAP has different isoforms which are differentially expressed in
tissues as a result of differential splicing (89). These isoforms,
as one might speculate, have different functions under different
cell physiological contexts or between different cell types. In fact,
most of the publications that studied YAP function in cancer did
not acknowledge which YAP isoform was used or investigated,
which makes it difficult to compare findings obtained from
these different studies. For example, overexpression of hYAP1-
2γ in mammary gland cells promotes oncogenic phenotypes
including protection from apoptosis (89). On the other hand,
overexpression of hYAP1-2α in squamous carcinoma cells
induced apoptosis (90). Moreover, in a recent paper that studied
the transcriptional potencies of YAP isoforms, it was shown that
splice variant insertions in the C-terminus, which lead to the
disruption of YAP leucine zipper, decreased YAP transcriptional
activity (91). In conclusion, the discrepancy about YAP function
in breast cancer and the presence of different YAP isoforms that
seem to have different effects on the Hippo pathway signaling,
ensures the need for better understanding of the role of the
different YAP isoforms in breast cancer. This will help in the
development of better YAP/TAZ based potential breast cancer
treatments.
E3 UBIQUITIN LIGASES AND BREAST
CANCER
Ubiquitination is an important post translation modification
that alters protein function, either by destabilizing it, or
through changing its subcellular localization. The fate of
the ubiquitinated protein seems to depend on the length
and architecture of the ubiquitin chain. For example, while
K48-linked polyubiquitin chains mediate protein degradation
in the proteasome, K63-linked polyubiquitin chains change
protein subcellular localization under different cell physiological
situations (92). E3s can be generally classified into three
subfamilies: (1) The homologous to E6-AP carboxyl terminus
(HECT) domain-containing E3s; (2) Finger domain-containing
E3s and; (3) and the U box E3s (2). Ubiquitination involves
a cascade of reactions catalyzed by 3 different enzymes;
E1 (ubiquitin activating), E2 (ubiquitin conjugating) and E3
(ubiquitin ligating) enzymes. The specificity of this reaction is
determined by the E3 ligase, which binds in a specific manner to
a specific substrate. Ubiquitination is involved in many biological
processes including DNA damage response, cell proliferation,
apoptosis, cell cycle, transcription, and immune response (93–
96). Deteriorations in the ubiquitination system are connected to
the development of different diseases including; autoimmunity,
and inflammatory diseases (97), neurodegeneration (98) cardiac
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diseases (99), and cancer (1, 2, 93, 100). In cancer, the ubiquitin
system regulates different cellular processes and targets involved
in carcinogenesis including cell cycle, p53, transcription, DNA
repair, cell signaling and apoptosis.
NEDD4 or NEDD4-like E3s interacts with their target
proteins via their WW domains. These E3s are involved in
different processes in different types of cancer including breast
cancer as discussed below.
E3s Role in Breast Cancer Growth and
Survival
Estrogen receptor alpha (ERα) is expressed in almost 70% of
breast cancers and promotes estrogen-dependent cancer cell
proliferation and tumor progression. Recently, it was shown that
Secondary Metabolite Unique Regions Finder 1 (SMURF1), via
its HECT domain, interacts with and stabilizes ER, and that
depletion of SMURF1 decreases ERα-positive cell proliferation in
vitro and in vivo (101). This pro-proliferative and pro-oncogenic
effect of SMURF1 in breast cancer was found to be the case with
SMURF2 too (Figure 6). SMURF2 silencing in human breast
cancer cells results in a low tumorigenicity of the cells in vitro,
and also, arrests cells in G0/G1 phase of cell cycle (102). Analysis
of the mechanism that results in these phenotypes revealed that
SMURF knockdown destabilizes CNKSR2 (connector Enhancer
Of Kinase Suppressor Of Ras 2) protein in the cell. Of note, this
effect is mediated by WW domain protein-protein interaction
(102). Another E3 that was connected to breast cancer cell
proliferation is WWP1. WWP1 enhances cell proliferation
after polyubiquitination and proteosomal degradation of LATS1
(Figure 6) (103, 104). In this context, while over-expression of
WWP1 enhances cell proliferation in LATS1-positive MCF10A
mammary epithelial cells, knockdown of WWP1 in MCF7 breast
cancer cells reduces their proliferation (103, 104). Also, WWP1
supports cell proliferation and survival by targeting ErbB4 for
proteosomal degradation (105, 106). This pro-proliferative effect
of WWP1 on breast cancer is in concordance with other results
that showed thatWWP1 stabilizes ER (Figure 6), which supports
cell proliferation in ER+ cells. When WWP1 is knocked down,
cells become more sensitive to tamoxifen treatment (103). While
all the studies discussed above point out to the fact that WWP1
is a pro-proliferative factor, two independent studies published
by the same group showed that WWP1 might have an anti-
proliferative role through targeting KLF5 (Figure 6), which is a
transcription factor that promotes breast cell proliferation and
survival (107, 108). In these studies, both YAP (107) and TAZ (48)
prevented the E3 ubiquitin ligase WWP1 from ubiquitinating
and sending KLF5 for degradation (Figure 6). Recently, Lim et al.
demonstrated that ITCH overexpression reverses breast cancer
progression mediated byWnt signaling. The authors showed that
wnt signaling blocks ITCH mediated degradation of YAP/TAZ
transcriptional coactivator WBP2 (Figure 6), and thus promotes
breast cancer cell proliferation (109). On the same principle, but
utilizing a different mechanism, in a different cellular context,
Amot130 and ITCH were shown to promote the ubiquitination,
degradation and inhibition of YAP function in response to serum
starvation (110) (Figure 6).
E3s Modulate Breast Cancer Cell
Migration, Invasion, and Metastasis
WW domain-containing E3s function in tumor metastasis was
also established. Analysis of the expression level of SMURF2
protein revealed that it is elevated in 30% of mammary ductal
carcinomas as well as in aggressive and metastatic breast cancer
cell line MDA MB231 (111). In this article, it was disclosed that,
while SMURF2 knockdown lowers aggressiveness and motility
of breast cancer cells, its overexpression promotes metastasis
in vivo and in vitro (111). These findings are supported by
results obtained by David et al. (102), who showed a high
expression level of SMURF2 in the aggressive MDA-MB-231 cell
line compared to other less aggressive cancer cell lines. Moreover,
they showed that SMURF2 silencing in human breast cancer
cells decreases cell migration/invasion in vitro (102). Also, in
tissue samples, SMURF2 protein levels were high in infiltrating
ductal carcinoma when compared to normal tissue. These
findings support the notion that SMURF2 supports invasiveness
and metastasis in breast cancer. In fact these findings are in
controversy with a publication by Liu (112), which demonstrated
that SMURF2 expression is downregulated in triple negative
metastatic tumors in comparison with either benign lesions or
ductal carcinoma in situ. Also, human triple-negative breast
cancer cell lines such as BT549, MDA-MB-436, DU-4475 and
MDA-MB-468 cells showed significantly lower expression of
SMURF2 protein, compared to ER + or HER2+ cell lines (112),
indicating that SMURF2 might play an inhibitory function in
the context of breast cancer invasion and metastasis. Indeed, two
other studies supported this notion. in these studies, SMURF2
knockdown was shown to lead to a more aggressive and more
migratory metastatic phenotypes in vitro and in vivo (113,
114). Interestingly, in one of these studies, SMURF2 inhibited
cell invasiveness by reducing SMURF1 levels (113). In line
with these finding, SMURF1 was shown to be important for
EGF mediated cell migration and invasion (114). In addition,
SMURF1 expression is elevated and required for MDA-MB-231
breast cancer cells motility. In these cells, Ubiquitin Specific
Peptidase 9 X-Linked (USP9X) stabilizes endogenous SMURF1,
and depletion of USP9X leads to down-regulation of SMURF1
and significantly impaired cellular migration (Figure 7) (115).
Another WW domain containing E3 ligase that was shown to
play a role in breast cancer migration and metastasis is WWP1.
WWP1 knockdown in MDA-MB-231 breast cancer cells results
in more osteolytic lesions and increases tumor area in bone
marrow of mice when injected into the left ventricle of the
heart (116). In this study, WWP1 knockdown reduced CXCL12-
induced CXCR4 lysosomal trafficking and degradation (Figure 7)
(116). These results proved that WWP1 inhibits breast cancer
cell metastasis to the bone. ITCH E3 ligase was also connected
to tumor invasion and metastasis. It was shown that in order
to mediate TGF-β-induced breast cancer invasion, ITCH must
degrade Ras association domain family 1 isoform A (RASSF1A)
(Figure 7). As a consequence, Hippo pathway effector YAP1
associates with SMADs and results in their nuclear translocation
(117). The pro-tumorigenic activities of ITCH were shown to
be mediated also through LATS1. ITCH was shown to interact
with LAST1 and send it to proteosomal degradation. As a
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FIGURE 6 | E3 ligases regulate breast cancer cell proliferation. In breast cancer, both, WWP1 and SMURF1 stabilize ER and enhances its activation. WWP1 can also
ubiquitinate and degrade LATS1 and liberates YAP/TAZ transcriptional activities. In contrast to this WWP1 can also target the pro-proliferative factor KLF5 and inhibit
cell growth. This WWP1 activity can be inhibited by YAP and TAZ. SMURF2 supports cell proliferation by activating the PI3K-A-AKT-FoxO3 pathway. ITCH with
angiomotin lead to YAP degradation and inhibits YAP proliferative activities. Wnt signaling inhibits WBP2 degradation by ITCH, and increases its transcription
transactivation function. All these are mechanisms that activate cell cycle and transcription of pro-proliferative genes.
consequence, LATS1 degradation mediates YAP translocation
into the nucleus and induces its transcriptional activities. This
YAP activation induces EMT and breast cancer invasion and
metastasis in vitro and in vivo (34, 35).
Apoptosis
Previous studies that investigated WWP1 expression level in
breast cancer revealed that WWP1 knockdown significantly
induces cell growth arrest and apoptosis in breast cancer cell
lines by activating different caspases. In addition, it was found
that overexpression of WWP1 in immortalized breast epithelial
cell lines MCF10A and 184B5 promotes cell proliferation (118).
In concordance with these findings, it was found that WWP1
depletion activates the TNF-related apoptosis-inducing ligand
(TRAIL) extrinsic apoptotic pathway (Figure 1). Moreover, a
correlation was found between the expression levels of WWP1 in
four breast cancer cell lines and TRAIL resistance, but not tumor
necrosis factor alpha (TNFα) and doxorubicin resistance (108).
Another E3 ligase that plays a role in apoptosis is ITCH, which
interacts with and destabilizes the tumor suppressor gene Ras
association domain family Member 5 (RASSF5). This interaction
inhibits RASSF5-mediated G1 phase transition of cell cycle as
well as apoptosis (119) (Figure 1).
E3s and Genomic Stability
SMURF2−/− aging mice develop different types of tumors
including breast cancer. In an attempt to explain this phenotype,
it was discovered that SMURF2 deletion leads to the stabilization
of the RNF20/hBre1A (Figure 2), the major ubH2B-specific E3.
This upregulation of RNF20 leads to changes in chromatin
landscape and genomic instability (120). Furthermore, the same
group elucidated that SMURF2, by stabilizing Topoisomerase
FIGURE 7 | E3 modulate breast cancer cell invasion and metastasis. EGF
induces the activity of ERK signaling pathway that increases SMURF1
pro-invasive activities. SMURF1 is also stabilized by USP9X. SMURF2 has
both pro- and anti- invasive and metastatic functions. By inhibiting SMURF1,
SMURF2 inhibits cell invasion and metastasis. On the other hand SMURF2
was shown to induce cell invasion and metastasis. WWP1 reduces bone
metastasis by inhibiting CXCR4. ITCH induction by TGF-β or other unknown
mechanisms promotes cell invasion and metastasis by sending RASSF1 and
LATS1 (Hippo pathway activators) for proteosomal degradation.
IIa (Topo IIa) (Figure 2), protects cells from DNA damage and
genomic instability. They also found that SMURF2-depletion
leads to reduced cell ability to resolve DNA catenanes and to
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pathological chromatin bridges formed during mitosis, which
are traits that were observed in Topo II deficient cells and are
also a hallmark of chromosome instability (121). ITCH was also
connected to genomic stability. In response to DNA damage,
ITCH activity leads to nuclear accumulation of WWOX through
its K63-linked ubiquitination at lysine residue 274. Nuclear
WWOX then interacts with ATM or ATR (under different types
of insults) and enhances their activation and thus enhances
cellular DNA damage response and genomic stability (Figure 2)
(23, 24).
E3s and Breast Cancer Therapy
As described above, E3s are involved in many cancer related
processes. Thus, they might be good targets for cancer treatment.
However, some facts might limit the potential of E3s to be
targets for cancer therapy. For instance, E3s can play antagonistic
effects under different cellular contexts. For example, ITCH
was shown to have both, anti-tumorigenic as well as pro-
tumorigenic activities by targeting different proteins. More than
that, some E3s can target related proteins that have antagonistic
functions. For example p63 is a WWP1 target. p63 has different
isoforms that are differentially expressed in different tissues
and can have even opposite functions. For example, while
TAp63 is believed to sensitize cells to apoptosis, DNp63 has an
opposite function. It was found that WWP1 ubiquitinates, and
destructs both DNp63α and TAp63alpha. While knockdown of
WWP1 increases the DeltaNp63α levels in the MCF10A and
184B5 immortalized breast epithelial cell lines and conferred
resistance to doxorubicin-induced apoptosis, knockdown of
WWP1 increases TAp63α level, induces apoptosis, and increases
sensitivity to doxorubicin and cisplatin in the HCT116 colon
cancer cell line (122). In addition to these limitations, it is
well documented that a specific E3 ligase can target different
substrates, which to a certain extent reduces the approach
specificity and may predict the presence of side effects for E3s
based therapies. Moreover, different types of ubiquitinations
can result in different effects. For example while K48 type
of ubiquitination is usually connected to protein degradation,
K63 usually changes protein function and localization. The
way the type of the ubiquitination is being selected under
different cellular contexts is another issue that might impede the
development of E3s based therapies. Another issue that needs to
be addressed when trying to look for therapeutic targets related
to ubiquitination is the fact that different E3s can have different
isoforms. In breast cancer cell line T47D, six isoforms of WWP1
have been identified (123). These isoforms were shown to have
different domain structures. Some of these isoforms contain
or lack an N-terminal C2 domain. The distribution of these
isoforms is tissue specific (123). Consequently, Flasza et al. raised
the possibility that alternative forms are targeted to different
locations in the cell, and thus may possibly regulate target protein
selection. This means that an E3 might have different targets in
different tissues or under different cellular contexts.
Chemo resistance is one important mechanism that impedes
successful cancer treatment. E3s were also tied to chemo
resistance (124). For example, WWP1 was shown to inhibit
TRAIL induced apoptosis in breast cancer cell lines (108).
Moreover, WWP1 was shown to stabilize p53 and leads
to its exportation to the cytoplasm and thus inhibiting
its transcriptional activity (108). These findings suggest that
WWP1manipulation in p53 wild type breast cancer tumors can
sensitize them to anti-cancer treatment (125).
Another example on the link between E3s and response to
therapy is ITCH. In a recent publication, ITCH was shown
to sensitize ER+ breast cancer cells, who acquired resistance
to endocrine treatment (126). In this study, the transition
from an endocrine therapy sensitive to a resistant state was
accompanied with c-Jun N-terminal kinases (JNK) activation.
This JNK activation seemingly resulted in ITCH phosphorylation
and activation and thus c-FLIP degradation (126). In another
study, in an attempt to characterize the mechanism of action of
the neuregulin-non-competitive anti-HER3 therapeutic antibody
9F7-F11 that blocks the PI3K/AKT pathway and induces cell
cycle arrest and apoptosis of breast cancer, it was found that
9F7-F11 activates JNK and consequently ITCH. This ITCH
activation was shown to induce rapid HER3 down-regulation
(127). Also, several ITCH inhibitors were identified in high
throughput screening for putative ITCH modulators. One of
these identified ITCH inhibitors was clomipramine—a clinically
useful antidepressant drug. Treatment of different cancer cell
lines including breast cancer cell lines with clomipramine, or
its homologs, reduced cancer cell growth, and synergized cancer
cell killing by gemcitabine or mitomycin by blocking autophagy
(128). In conclusion, these findings and others indicate that
E3s themselves can be targets for cancer therapies, or can be
biomarkers for the prediction of a specific therapy response.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
In conclusion, studies reviewed here demonstrate that WW
domain-containing proteins are critical players in breast cancer
initiation and progression. As discussed above, WW domain-
containing proteins can act as singles, or involved in the
assembly of signaling complexes like in the case of the Hippo
pathway. They can act as oncogenes or tumor suppressors by
altering different cancer related processes. However, some of
WW domain-containing proteins could act as either tumor
suppressors or oncogenes with some controversies about the
identity of some of these proteins.
As we discussed above, these controversies about the functions
of some of WW domain-containing proteins could be related
not only to cell context, but also to their interactions and their
partners. Moreover, we explained that these controversies could
stem from the presence of different isoforms of the same protein.
These isoforms can have different cell and tissue distribution
patterns and thus may have different partners and targets. Thus,
in future research, it might be very important and necessary to
mention or identify the isoform studied in a specific context.
For example the current literature does not specifically mention
which YAP or WWP1 isoform(s) are addressed in a specific
study, which makes it difficult compare and judge controversial
results obtained. These controversies and different functions of
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these proteins can be resolved also by future studies that will be
based on more global approaches that will study the proteome or
even the interactomes of these proteins in different cell contexts
and in relation to different cancer related processes regulated
by WW domain-containing proteins. Such studies, in addition
to illustrating the mechanism(s) of action of the different WW
domain-containing proteins, they will identify other biomarkers
involved in the execution of phenotypes related to the different
WW domain-containing proteins. In fact the identification of
such biomarkers and elucidation of exact mechanism of action
can be also beneficial in the prediction of therapeutic outcomes
related to the manipulation of WW domain-containing proteins
in the future.
Another future direction that should be followed in the
context of WW domain-containing proteins and breast cancer
is the identification of new such proteins. It is predicted that
there are many other different WW domain-containing proteins
that will have impact on breast tumorigenesis. The fishing for
such proteins can be based on pulling down WW proteins using
known PY rich domains, or by developing and using different
softwares to help predict the presence of WW proteins in the
human genome.
The use of WW domain-containing proteins as drug targets
is still a premature idea that needs intensive future research.
In this regard, one can raise the question of what to target
in these proteins? Shall a drug target the catalytic activity of
these proteins? Or their interactions by targeting their WW
domains? Or target even their partners and targets? The answer
to these questions will never be easy with our current knowledge
about these proteins. However, we can speculate about the
complexity in choosing which proposed strategy would be a
successful one. For example, upon targeting the catalytic domain
of different WW domain-containing proteins, a drug can target
different proteins that have antagonistic functions in the context
of cancer. For instance, if drugs were developed to target the
evolutionary-conserved catalytic HECT domain, these drugs will
target for example SMURF1 and SMURF2, which were shown
to have antagonistic functions in breast carcinogenesis, and
this, theoretically, might make such a strategy a failing one. In
choosing to target WW domains in order to disrupt protein-
protein interaction is also complex. Although there are different
types of WW domains, there is still redundancy regarding the
presence of a specific type of WW domain in different proteins,
and thus it is expected that upon targeting the interaction
of a specific WW domain-containing protein, the interactions
of different other WW domain-containing proteins will be
affected. In this context, here, another issue is present, which
is the presence of usually more than one WW domain in one
protein. These domains do not seem to be redundant in their
interactions. On the contrary, they seem to be very specific which
raises another question; Which domain in a specific protein to
target? Regarding the last possibility of targeting WW domain-
containing protein partners as means of therapeutic intervention,
it might seem to be the best option. Although the fact that
different WW domain-containing proteins can partner with
common and shared partners, there are different examples for the
presence of specific targets for different WW domain-containing
proteins. These specific targets might act as biomarkers to
predict specific treatment success or even be a therapeutic
target.
Finally, it is obvious that WW domain-containing proteins
are critical factors in breast carcinogenesis and that a better
understanding of their roles in breast cancer will likely lead to the
identification and development of biomarkers and drug targets
for cancer treatment.
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